Compare Cognizant Technology Solutions Corp (CTSH) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cognizant Technology Solutions Corp vs Zoetis Inc — how do they compare? Cognizant Technology Solutions Corp trades at $58.99 (market cap $26.40B), while Zoetis Inc trades at $73.66 (market cap $31.14B). The key difference: Zoetis Inc is the larger of the two by market cap, and Zoetis Inc pays the higher dividend (2.81%). Which is the better fit depends on your goals.
| CTSH | ZTS | |
|---|---|---|
Market Cap | $26.40B | $31.14B |
Sector | Technology | Health |
52-Week High | $86.70 | $156.76 |
52-Week Low | $38.73 | $71.91 |
Enterprise Value | $27.44B | $38.70B |
Dividend Yield | 2.25% | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cognizant (CTSH) trades at $58.19, down 0.21% today, with a bullish technical signal and strong cash flow. Recent Q2 2026 earnings missed estimates at $1.37 EPS, but revenue beat. The company maintains a solid net income margin of 10.26% and trades at a P/E of 12.58, below industry averages. Analyst consensus is mixed with a $59.92 price target, and the stock shows resilience amid AI-driven strategic shifts.
Outlook remains cautiously optimistic with upside potential from AI initiatives and financial services growth, though risks include client spending caution and competitive pressures. The stock's current valuation offers a margin of safety, but investors should monitor execution on AI integration and macroeconomic headwinds affecting IT spending.
Zoetis (ZTS) trades at $73.4, down 1.95% on the day, as technical indicators signal a bearish trend amid recent price weakness. Fundamentally, the company reported Q2 2026 EPS of $1.87, beating estimates, but revenue was flat and full-year guidance was cut due to softer pet healthcare demand. Analyst sentiment remains mixed with a consensus price target of $94.90, though recent news highlights competitive pressures and a securities class action lawsuit.
The stock presents a value opportunity given its attractive P/E of 12.29 and strong profitability margins, but near-term headwinds from U.S. companion-animal market challenges and legal overhangs pose risks. Upside depends on execution against revised 2026 targets and stabilization in core markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cognizant Technology Solutions Corp
Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 300,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.
Read more on CTSH →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
